# A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

> **NCT06362096** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Huihua Xiong** · enrollment: 72 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab+pyrotinib+taxene

## Key facts

- **NCT ID:** NCT06362096
- **Lead sponsor:** Huihua Xiong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2025-05
- **Final completion:** 2026-05
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362096, "A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06362096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*